XORTX Therapeutics Changes Auditor
Ticker: XRTX · Form: 6-K · Filed: Jan 22, 2025 · CIK: 1729214
Sentiment: neutral
Topics: auditor-change, administrative
TL;DR
XORTX swapped auditors, Davidson out, Smythe in, effective Jan 21.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on January 22, 2025, to report a change in its auditor. The company has appointed Smythe LLP as its new auditor, replacing Davidson & Company LLP. This change is effective as of January 21, 2025.
Why It Matters
A change in auditor can sometimes signal underlying issues or a strategic shift within a company, potentially impacting investor confidence.
Risk Assessment
Risk Level: low — This filing solely concerns a routine administrative change in the company's auditing firm and does not involve financial performance or strategic operational changes.
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Smythe LLP (company) — Successor Auditor
- Davidson & Company LLP (company) — Former Auditor
- Allen Davidoff (person) — Chief Executive Officer
- January 21, 2025 (date) — Effective date of change
- January 22, 2025 (date) — Filing date
FAQ
Who is the new auditor for XORTX Therapeutics Inc.?
The new auditor for XORTX Therapeutics Inc. is Smythe LLP.
Who was the former auditor of XORTX Therapeutics Inc.?
The former auditor of XORTX Therapeutics Inc. was Davidson & Company LLP.
When was the change of auditor effective?
The change of auditor was effective as of January 21, 2025.
What type of filing is this?
This is a Form 6-K, Report of Foreign Private Issuer.
Who signed the report on behalf of XORTX Therapeutics Inc.?
Allen Davidoff, Chief Executive Officer, signed the report on behalf of XORTX Therapeutics Inc.
Filing Stats: 150 words · 1 min read · ~1 pages · Grade level 10 · Accepted 2025-01-22 13:34:26
Filing Documents
- f6k_012225.htm (6-K) — 7KB
- exh_991.htm (EX-99.1) — 4KB
- exh_992.htm (EX-99.2) — 1KB
- exh_993.htm (EX-99.3) — 1KB
- exh992.jpg (GRAPHIC) — 130KB
- exh993.jpg (GRAPHIC) — 146KB
- 0001171843-25-000371.txt ( ) — 396KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-40858 XORTX Therapeutics Inc. 3710 – 33 rd Street NW, Calgary, Alberta, T2L 2M1 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ⊠ Form 40-F □ SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XORTX THERAPEUTICS INC. (Registrant) Date: January 21, 2025 By: /s/ Allen Davidoff Name: Allen Davidoff Title: Chief Executive Officer EXHIBIT INDEX 99.1 51-102 - Notice of Change of Auditor 99.2 51-102 - Former Auditor Letter 99.3 51-102 - Successor Auditor Letter